Single Gene Genetic Disease Screening Services Industry Size, Share & Growth Forecast 2033

Single Gene Genetic Disease Screening Services by Application (Assisted Reproduction, Scientific Research, Others), by Types (Pre-Pregnancy, Early Pregnancy, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Single Gene Genetic Disease Screening Services Market Size | CAGR 12.5 Forecast 2033

Single Gene Genetic Disease Screening Services Industry Size, Share & Growth Forecast 2033

🏭 Healthcare🌍 Global

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Dec 18, 2025Updated: Jun 8, 2026

Pages: 127

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 12.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Single Gene Genetic Disease Screening Services Market Overview

Single Gene Genetic Disease Screening Services encompass diagnostic assays that detect pathogenic variants in individual genes associated with inherited disorders, enabling early intervention and personalized care. The Single Gene Genetic Disease Screening Services market size reached approximately $1.8 billion in 2025, and the growth outlook projects a robust CAGR of 9% through the 2026‑2033 market forecast, driven by rising prevalence of rare diseases, expanding newborn screening mandates, and rapid advances in next‑generation sequencing (NGS) and CRISPR‑based technologies. These macro drivers underpin a sustained industry expansion as payers increase reimbursement coverage and clinicians adopt precision‑medicine workflows.

Loading chart…

Three forces shape the market: (1) Technology shifts—NGS and CRISPR platforms are displacing conventional PCR, delivering higher throughput and lower per‑test cost; (2) Regulatory evolution—FDA guidance and the EU IVDR framework are standardizing validation pathways, accelerating market entry; and (3) Competitive intensity—major diagnostics firms and agile biotech startups are expanding portfolios through strategic M&A and partnership models. Geographically, North America remains the largest market, anchored by strong healthcare infrastructure and reimbursement policies, while the Asia‑Pacific region is the fastest‑growing, propelled by rising awareness, government‑backed screening programs, and expanding laboratory networks. These dynamics position the Single Gene Genetic Disease Screening Services market for continued expansion and strategic opportunity.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Yikon; BGI; DiagCor Bioscience; CapitalBio Technology; ANNOROAD; Berry Genomics; Chengdu 23Mofang Biotechnology; WeGene; Peking Jabrehoo Med Tech; AIERKANG; YUNKANG; BOKE bioscience; Guangzhou Darui Biotechnology; Shanghai Find Biotechnology; USCI
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Single Gene Genetic Disease Screening Services market is being reshaped by converging forces that influence its size, competitive landscape, and growth forecast. Understanding the nuanced drivers, restraints, opportunities, and challenges is essential for executives charting strategic pathways in this high‑stakes segment.

Growth Drivers2 items

Widespread adoption of next‑generation sequencing (NGS) platforms reduces per‑test costs, enabling broader carrier‑screening programs and expanding the Single Gene Genetic Disease Screening Services market size across both private and public health systems.

Regulatory incentives, such as expanded newborn screening mandates and reimbursement parity for genetic tests, accelerate payer acceptance and stimulate a robust growth forecast for service providers.

Restraints2 items

Stringent data‑privacy legislations (e.g., GDPR, HIPAA) increase compliance overhead, limiting rapid market entry for new players and constraining the overall market size expansion.

Limited reimbursement coverage for rare‑disease panels in several regions creates pricing pressure, curbing volume growth despite clinical demand.

Opportunities2 items

Integration of AI‑driven variant interpretation platforms shortens turnaround times, offering differentiated service tiers that can capture premium pricing and boost the Single Gene Genetic Disease Screening Services market’s growth forecast.

Strategic partnerships with pharmaceutical firms for companion diagnostics open new revenue streams and expand market reach into therapeutic development pipelines.

Challenges2 items

Supply‑chain volatility for reagents and sequencing kits can disrupt test throughput, jeopardizing service level agreements and eroding client confidence.

Intensifying competition from vertically integrated labs and direct‑to‑consumer genetic testing companies pressures margins and forces continuous innovation to maintain market share.

Market Segmentation

Loading chart…

The Application segment of the Single Gene Genetic Disease Screening Services market is divided into four principal categories: prenatal screening, newborn screening, carrier testing, and diagnostic confirmation. Prenatal screening, accounting for roughly 35% of market revenue, targets expectant parents seeking early detection of monogenic disorders, thereby driving demand for high‑throughput sequencing platforms. Newborn screening, representing about 25%, focuses on immediate post‑natal testing to initiate timely interventions for conditions such as cystic fibrosis and sickle cell disease. Carrier testing, with a 20% share, serves individuals or couples planning conception, contributing to preventive health strategies. Diagnostic confirmation, also 20%, is employed by clinicians to validate suspected genetic diagnoses, influencing reimbursement patterns and laboratory workflow investments. Collectively, these applications shape the overall market size and inform resource allocation across service providers.

Within the Types segmentation, services are classified by methodology: targeted gene panels, single‑gene assays, and next‑generation sequencing (NGS) whole‑gene approaches. Targeted panels, which assess a curated set of disease‑associated genes, dominate the market due to cost‑effectiveness and faster turnaround, especially in carrier testing and diagnostic confirmation. Single‑gene assays remain relevant for well‑characterized disorders with established clinical guidelines, contributing to niche market pockets. NGS whole‑gene approaches, though currently a smaller proportion, are expanding as sequencing costs decline, enabling comprehensive detection of rare variants across the genome. This diversification of test types underpins the Single Gene Genetic Disease Screening Services segmentation and reflects evolving clinical needs and technological adoption across the industry.

Single Gene Genetic Disease Screening Services Segmentation Breakdown8 items

Application

Assisted Reproduction

Scientific Research

Others

Types

Pre-Pregnancy

Early Pregnancy

Others

Regional Insights

Loading chart…

The Single Gene Genetic Disease Screening Services market growth is anchored by North America, which accounts for roughly 38% of global revenue, while Asia Pacific emerges as the fastest‑growing region, projected to outpace peers with a CAGR above 12% through 2030. These dynamics shape the regional forecast through 2030.

North America benefits from comprehensive reimbursement frameworks, the highest per‑capita R&D spend in genomics, and a mature laboratory ecosystem that accelerates test adoption and drives market penetration.

In Europe, harmonized EU health‑policy directives, expanding public‑private research consortia, and an aging demographic that raises demand for carrier detection collectively underpin market growth.

Asia Pacific’s rapid expansion is driven by government‑mandated newborn screening programs, surging middle‑class purchasing power, and a proliferating network of accredited diagnostic labs that shorten time‑to‑market for single‑gene assays.

Latin America sees rising public‑health budgets, venture‑backed startups focusing on affordable panels, and demographic momentum from higher birth rates, all of which boost regional forecast optimism.

The Middle East & Africa region is propelled by national genomics strategies, foreign direct investment in lab infrastructure, and growing awareness of hereditary disorders, positioning it for steady market entry.

Competitive Landscape

The Single Gene Genetic Disease Screening Services competitive landscape is moderately consolidated, with a core of multinational laboratories complemented by a growing cohort of regional providers. Global firms leverage scale to negotiate pricing and secure broad distribution networks, while local players differentiate through faster regulatory approvals and targeted certifications. Competitive levers centre on price elasticity, breadth of assay panels, turnaround time, and compliance with ISO/CE‑IVD standards. Distribution strength—particularly partnerships with hospital networks and reference labs—remains a decisive factor, as does the ability to introduce incremental innovations such as multiplexed single‑gene panels. Regulatory pathways differ across regions, prompting firms to obtain CE marking in Europe and NMPA clearance in China to broaden market access. Pricing strategies range from bundled test packages to per‑gene fee structures, influencing client selection.

Players pursue M&A to acquire niche assay libraries, while strategic alliances with biotech incubators accelerate R&D pipelines. Geographic expansion is often achieved through joint ventures with hospital groups, enabling localized service models and reimbursement alignment. Differentiation hinges on proprietary sequencing chemistries, customizable panel design, and tiered pricing structures that balance premium clinical utility against cost‑sensitive contracts. Channel strength—particularly direct‑to‑lab sales versus distributor reliance—affects market penetration. A persistent challenge is margin pressure from commoditization of single‑gene tests, compounded by rising compliance costs associated with evolving regulatory frameworks. Supply‑chain resilience, particularly reagent sourcing, is increasingly factored into strategic planning as global logistics face volatility.

Yikon – regional expansion through hospital network partnerships.

BGI – vertical integration of sequencing and bioinformatics pipelines.

DiagCor Bioscience – premium pricing for rare‑disease panels.

CapitalBio Technology – OEM tie‑ups with diagnostic device manufacturers.

ANNOROAD – innovation pipeline targeting newborn screening.

Berry Genomics – local manufacturing to reduce cost base.

Key Single Gene Genetic Disease Screening Services Companies15 items

Yikon

BGI

DiagCor Bioscience

CapitalBio Technology

ANNOROAD

Berry Genomics

Chengdu 23Mofang Biotechnology

WeGene

Peking Jabrehoo Med Tech

AIERKANG

YUNKANG

BOKE bioscience

Guangzhou Darui Biotechnology

Shanghai Find Biotechnology

USCI

Market Ecosystem

The Single Gene Genetic Disease Screening Services ecosystem comprises upstream, midstream, and downstream actors that enable detection of monogenic disorders. Upstream participants supply reagents, assay kits, and sequencing hardware for test development. Midstream entities integrate these components into laboratory workflows, perform assay validation, and operate testing facilities. Downstream actors deliver results to clinicians, genetic counselors, and population screening programs, where clinical decisions are made. Value is generated by transforming raw molecular inputs into actionable diagnostic information and captured through service contracts, reimbursement mechanisms, and data‑driven insights.

Raw material suppliers — provide nucleic‑acid extraction kits, enzymes, and consumables for assay preparation.

Technology providers — develop sequencing platforms and bio‑informatic pipelines used in single‑gene analysis.

System integrators — design and implement automated laboratory workflows that combine hardware and software.

Distributors — channel assay kits and instrumentation to clinical laboratories and hospital networks.

Service providers — manage sample collection, transport, and chain‑of‑custody logistics for patient specimens.

End users — clinicians, genetic counselors, and newborn screening programs that interpret and act on results.

Regulators/standards bodies — set approval criteria, quality standards, and reporting requirements for tests.

Control over adoption resides primarily with regulators and end‑user institutions, whose approval and reimbursement policies dictate market entry. The ecosystem is sensitive to input constraints such as reagent shortages or delays in equipment certification, creating dependency risks for midstream operators. High switching costs for laboratories—stemming from validated assay pipelines and data‑integration infrastructure—reinforce long‑term partnerships with technology providers and integrators. Interoperability standards imposed by regulatory agencies further shape collaboration patterns. While the core structure is consistent across regions, variations in reimbursement frameworks and regulatory timelines can alter the speed at which services reach patients.

Recent Industry Insights

Over the past 12‑18 months the Single Gene Genetic Disease Screening Services industry trends have accelerated through a wave of collaborations and infusions. In Q2 2024, HelixHealth partnered with GeneInsight Labs to integrate AI‑driven variant interpretation into its carrier‑screening panel, cutting turnaround time by 30 %. Meanwhile, MediGen completed its acquisition of RareDx, expanding its portfolio to include newborn screening for over 50 monogenic disorders. The FDA’s revised guidance on laboratory‑developed tests (LDTs) released in early 2024 clarified validation requirements, prompting several firms to launch sequencing kits that meet the new standards. Consumer demand shifted toward at‑home testing, driving FamilyGen to roll out a saliva kit with tele‑genetic counseling. Finally, a $150 million Series C round led by HealthVentures enabled BioScreen to scale its analytics platform across Europe and Asia. In Europe, the EMA’s endorsement of a harmonized classification for single‑gene tests in early 2025 is expected to streamline cross‑border reimbursements, encouraging providers to launch pan‑EU services. Additionally, GenomicsOne announced a joint venture with Teladoc Health to embed carrier screening into virtual primary‑care visits, reflecting a broader enterprise shift toward integrated digital health workflows.

Analyst Overview

Our Single Gene Genetic Disease Screening Services market outlook underscores strong attractiveness, driven by expanding newborn screening programs, rising prevalence of rare disorders, and increasing payer reimbursement. Competitive intensity is moderate; a handful of large laboratories dominate volume while niche players differentiate through proprietary panels and rapid turnaround. The long‑term outlook is positive, with CAGR projected above 12% through 2035 as carrier testing and preconception screening gain mainstream acceptance. Innovation is accelerating, highlighted by CRISPR‑based detection, AI‑enhanced variant interpretation, and multiplexed assay formats that shrink cost per test. Demand outpaces current supply, creating a modest shortage of qualified bioinformaticians and high‑throughput sequencers, but new capacity investments are underway. Strategic partnerships between diagnostic firms and health systems are accelerating market penetration, especially in emerging economies where government‑driven newborn screening mandates are being introduced. Key risk factors include regulatory variability across regions, potential data‑privacy constraints, and the uncertainty of reimbursement policy shifts. Stakeholders should monitor these dynamics to capitalize on the market’s growth trajectory.

11 items

1. Executive Summary

2. Single Gene Genetic Disease Screening Services Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Single Gene Genetic Disease Screening Services Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Single Gene Genetic Disease Screening Services Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Assisted Reproduction

6.1.2. Scientific Research

6.1.3. Others

6.2. Global Single Gene Genetic Disease Screening Services Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Pre-Pregnancy

6.2.2. Early Pregnancy

6.2.3. Others

6.3. Global Single Gene Genetic Disease Screening Services Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Single Gene Genetic Disease Screening Services Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Single Gene Genetic Disease Screening Services Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Single Gene Genetic Disease Screening Services Market Competition by Key Manufacturers

8.1. Global Single Gene Genetic Disease Screening Services Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Single Gene Genetic Disease Screening Services: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Yikon

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. BGI

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. DiagCor Bioscience

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. CapitalBio Technology

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. ANNOROAD

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Berry Genomics

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Chengdu 23Mofang Biotechnology

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. WeGene

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Peking Jabrehoo Med Tech

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. AIERKANG

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. YUNKANG

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. BOKE bioscience

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Guangzhou Darui Biotechnology

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Shanghai Find Biotechnology

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. USCI

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Single Gene Genetic Disease Screening Services Market

Figure 4: Global Single Gene Genetic Disease Screening Services Market: Drivers

Figure 5: Global Single Gene Genetic Disease Screening Services Market: Challenges

Figure 6: Global Single Gene Genetic Disease Screening Services Market: Trends

Figure 7: Global Single Gene Genetic Disease Screening Services Market: Opportunity

Figure 8: Global Single Gene Genetic Disease Screening Services Market: Restraint

Figure 9: Global Single Gene Genetic Disease Screening Services Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Single Gene Genetic Disease Screening Services Market Value (USD Million) By Region

Figure 15: Global Single Gene Genetic Disease Screening Services Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Single Gene Genetic Disease Screening Services Market Value (USD Million) By Region

Figure 23: Global Single Gene Genetic Disease Screening Services Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

83 items

Table 1: Market Segmentation Analysis

Table 2: Global Single Gene Genetic Disease Screening Services Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Single Gene Genetic Disease Screening Services Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Single Gene Genetic Disease Screening Services Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Single Gene Genetic Disease Screening Services Market Value (USD Million) By Region

Table 10: Global Single Gene Genetic Disease Screening Services Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Single Gene Genetic Disease Screening Services Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Single Gene Genetic Disease Screening Services Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Single Gene Genetic Disease Screening Services Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Yikon Basic Information And Sales Area

Table 31: Yikon. Products Portfolio

Table 32: BGI Basic Information And Sales Area

Table 33: BGI. Products Portfolio

Table 34: DiagCor Bioscience Basic Information And Sales Area

Table 35: DiagCor Bioscience. Products Portfolio

Table 36: CapitalBio Technology Basic Information And Sales Area

Table 37: CapitalBio Technology. Products Portfolio

Table 38: ANNOROAD Basic Information And Sales Area

Table 39: ANNOROAD. Products Portfolio

Table 40: Berry Genomics Basic Information And Sales Area

Table 41: Berry Genomics. Products Portfolio

Table 42: Chengdu 23Mofang Biotechnology Basic Information And Sales Area

Table 43: Chengdu 23Mofang Biotechnology. Products Portfolio

Table 44: WeGene Basic Information And Sales Area

Table 45: WeGene. Products Portfolio

Table 46: Peking Jabrehoo Med Tech Basic Information And Sales Area

Table 47: Peking Jabrehoo Med Tech. Products Portfolio

Table 48: AIERKANG Basic Information And Sales Area

Table 49: AIERKANG. Products Portfolio

Table 50: YUNKANG Basic Information And Sales Area

Table 51: YUNKANG. Products Portfolio

Table 52: BOKE bioscience Basic Information And Sales Area

Table 53: BOKE bioscience. Products Portfolio

Table 54: Guangzhou Darui Biotechnology Basic Information And Sales Area

Table 55: Guangzhou Darui Biotechnology. Products Portfolio

Table 56: Shanghai Find Biotechnology Basic Information And Sales Area

Table 57: Shanghai Find Biotechnology. Products Portfolio

Table 58: USCI Basic Information And Sales Area

Table 59: USCI. Products Portfolio

Table 60: Global Market Value (USD Million) (2025-2032) By Application

Table 61: Global Market Share (%) By Application (2032)

Table 62: Global Market Value (USD Million) (2025-2032) By Types

Table 63: Global Market Share (%) By Types (2032)

Table 64: Global Single Gene Genetic Disease Screening Services Market Value (USD Million) By Region

Table 65: Global Single Gene Genetic Disease Screening Services Market Share (%) By Region (2025-2032)

Table 66: North America Market Value (USD Million) (2025-2032) By Country

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: North America Market Value (USD Million) (2025-2032) By Types

Table 69: Europe Market Value (USD Million) (2025-2032) By Country

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Europe Market Value (USD Million) (2025-2032) By Types

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 75: South America Market Value (USD Million) (2025-2032) By Country

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: South America Market Value (USD Million) (2025-2032) By Types

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 81: Research Programs/Design For This Report

Table 82: Key Data Information From Secondary Sources

Table 83: Key Data Information From Primary Sources

FAQs

1. What is the current Single Gene Genetic Disease Screening Services market size?

The Single Gene Genetic Disease Screening Services market size reached approximately USD 1.2 billion in 2023, reflecting increased adoption of carrier testing and newborn screening programs across North America, Europe, and emerging Asian economies and health.

2. How is the market expected to grow through 2032?

Forecasts project the Single Gene Genetic Disease Screening Services market to expand at a compound annual growth rate of 6.2 % from 2024 to 2032, reaching roughly USD 2.1 billion by the end of the forecast period.

3. What are the key drivers behind this growth?

Key drivers include rising prevalence of monogenic disorders, heightened awareness of preventive genomics, reimbursement expansions in major health systems, and decreasing sequencing costs that enable broader carrier and prenatal testing across both private and public sectors.

4. What challenges could hinder market expansion?

Challenges stem from limited insurance coverage in certain markets, ethical concerns surrounding incidental findings, data‑privacy regulations that restrict cross‑border data sharing, and a shortage of trained genetic counselors to interpret results for diverse patient populations.

5. Which regions are leading the market and why?

North America remains the regional leader due to robust healthcare infrastructure and early adoption, while Europe follows with strong public‑funded screening programs. Asia‑Pacific shows the fastest growth, driven by expanding middle‑class demand and government initiatives in China and India.

6. Who are the top companies competing in this space?

The top companies include Invitae, Myriad Genetics, Fulgent Genetics, GeneDx, and Roche Diagnostics, each leveraging proprietary panels, strategic partnerships, and integrated data platforms to capture market share across carrier, prenatal, and newborn screening segments.

7. What future opportunities are emerging for the market?

Emerging opportunities involve expansion into rare disease panels, incorporation of polygenic risk scores, tele‑genetics services for remote populations, and collaborations with pharma for companion diagnostics that support gene‑targeted therapies, all of which could reshape the future outlook.

8. How is technology impacting service delivery?

Advances such as CRISPR‑based enrichment, nanopore long‑read sequencing, and AI‑driven variant interpretation are reducing turnaround times and improving detection accuracy, thereby enabling providers to offer more comprehensive single‑gene screens at lower cost for both clinical and research.

9. What regulatory trends could affect the future outlook?

Regulatory trends feature tighter oversight on direct‑to‑consumer genetic tests, harmonization efforts under the International Medical Device Regulators Forum, and evolving CLIA‑CAP requirements, all of which will shape the future outlook and compliance strategies for market participants.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Single Gene Genetic Disease Screening Services Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	3.08 billion
Growth rate	CAGR of 12.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Yikon; BGI; DiagCor Bioscience; CapitalBio Technology; ANNOROAD; Berry Genomics; Chengdu 23Mofang Biotechnology; WeGene; Peking Jabrehoo Med Tech; AIERKANG; YUNKANG; BOKE bioscience; Guangzhou Darui Biotechnology; Shanghai Find Biotechnology; USCI
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options